Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer

Gynecologic Oncology

Volumn 63, Issue 3, 1996, Pages 312-317

  Goldberg, Jeffrey M ^a   Piver, M Steven ^a   Hempling, Ronald E ^a   Recio, Fernando O ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CREATININE; DEXAMETHASONE; DIPHENHYDRAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; MANNITOL; ONDANSETRON; PACLITAXEL; PHENOTHIAZINE; RANITIDINE;

ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; NEPHROTOXICITY; OVARY CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE; VOMITING;

EID: 0030561358     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0328     Document Type: Article

References (36)

1. 1. McGuire, W. P. Taxol: A new drug with significant activity as a salvage therapy in advanced epithelial ovarian cancer, Gynecol. Oncol. 51, 78-85 (1993).
2. 2. Piver, M. S., Lele, S. B., and Barlow, J. J. Weekly cis-dichlorodiammineplatinum (II): Active third-line chemotherapy in ovarian carcinoma -A preliminary report, Cancer Treat. Rep. 64, 1379-1382 (1980).
3. 3. Piver, M. S., Barlow, J. J., Lele, S. B., Malfetano, J. H., and McPhee, M. E. Cis-dichlorodiammineplatinum (II): Second-line induction chemotherapy in advanced ovarian adenocarcinoma. J. Surg. Oncol. 24, 9-31 (1983).
4. 4. Repetto, L., Chiara, S., Mammoliti, S., Guido, T., Bruzzone, M., Secondo, V., Donadio, G., Odicino, F., Ragni, N., Conte, P. F., and Rosso, R. Crossover study with cisplatin or carboplatin in advanced ovarian cancer, Gynecol. Oncol. 39, 146-149 (1990).
5. 5. Gore, M. E., Fryatt, I., Wiltshaw, E., Dawson, T., Robinson, B. A., and Calvert, A. H. Cisplatin/carboplatin cross-resistance in ovarian cancer, Br. J. Cancer 60, 767-769 (1989).
6. 6. Seltzer, V., Vogl, S., and Kaplan, B. Recurrent ovarian carcinoma: Retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent. Gynecol. Oncol. 21, 167-176 (1985).
7. 7. Gershenson, D. M., Kavanagh, J. J., Copeland, L. J., Stringer, C. A., Morris, M., and Wharton, J. T. Re-treatment of patients with recurrent ovarian cancer with cisplatin-based chemotherapy, Obstet. Gynecol. 73, 798-802 (1989).
8. 8. Parker, R. J., Dabholkar, M. D., Lee, K. B., Bostick-Bruton, F., and Reed, E. Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells, Monogr. Natl. Cancer Inst. 15, 83-88 (1993).
9. 9. Rowinsky, E. K., Citardi, M. J., Noe, D. A., and Donehower, R. C. Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine, J. Cancer Res. Clin. Oncol. 119, 727-733 (1993).
10. 10. Jekunen, A. P., Christen, R. D., Shalinsky, D. R., and Howell, S. B. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro, Br. J. Cancer 69, 299-306 (1994).
11. 11. Rustin, G. J. S., Nelstrop, A. E., McClean, P., Brady, M. F., McGuire, W. P., Hoskins, W. J., Mitchell, H., and Lambert, H. E. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125, J. Clin. Oncol. 14, 1545-1551 (1996).
12. 12. Wiltshaw, E., and Kroner, R. Phase II study of cis-dichlorodiammineplatinum (II) (NSC-119875) in advanced adenocarcinoma of the ovary, Cancer Treat. Rep. 60, 727-733 (1976).
13. 13. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics 1996. CA 46, 5-27 (1996).
14. 14. Rosen, G. F., Lurain, J. R., and Newton, M. Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy, Gynecol. Oncol. 27, 173-179 (1987).
15. 15. Manetta, A., MacNeill, C., Lyter, J. A., Scheffler, B., Podczaski, E. S., Larson, J. E., and Schein, P. Hexamethymelamine as a single second-line agent in ovarian cancer, Gynecol. Oncol. 36, 93-96 (1990).
16. 16. Vergote, I., Himmelman, A., Frankendal, B., Scheistroen, M., Vlachos, K., and Trope, C. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer, Gynecol. Oncol. 47, 282-286 (1992).
17. 17. Moore, D. H., Valea, F., Crumpler, L., and Fowler, W. C. Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian cancer, Gynecol. Oncol. 51, 109-112 (1993).
18. 18. Fields, A. L., Schink, J. C., Miller, D. S., Rademaker, A. W., and Lurain, J. R. Hexamethylmelamine: A well tolerated, effective salvage therapy for taxol in women with platinum resistant ovarian cancer, presented at the Western Association of Gynecologic Oncology, June 24, 1994.
19. 19. Barlow, J. J., and Piver, M. S. Second-line efficacy of intermediate high-dose methotrexate with citrovorum factor rescue + cyclophosphamide in ovarian cancer, Gynecol. Oncol. 7, 233-238 (1979).
20. 20. Markman, M., Hakes, T., Reichman, B., Lewis, J. L., Rubin, S., Jones, W., Almadrones, L., Pizzuto, F., and Hoskins, W. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease, J. Clin. Oncol. 10, 243-248 (1992).
21. 21. Dobbs, S. P., Gribbin, C., Chan, S. Y., and Bessell, E. M. Second-line treatment with ifosfamide and carboplatin in patients with ovarian carcinoma relapsing after treatment with carboplatin, Eur. J. Cancer 30A, 30-33 (1994).
22. 22. du Bois, A., Meerpohl, H. G., Madjar, H., Spinner, D., Dall, P., Pfisterer, J., and Bauknecht, T. Phase II study of pirarubicin combined with cisplatin in recurrent ovarian cancer, J. Cancer Res. Clin. Oncol. 120, 173-178 (1994).
23. 23. Chen, J., Hirai, Y., Shimizu, Y., Hasumi, K., and Masubuchi, K. New cisplatin schedule in combination with aclarubicin (ACR) with high response rate in recurrent gynecological adenocarcinomas. Gynecol. Oncol. 38, 1-5 (1990).
24. 24. De Lena, M., Lorusso, V., and Romito, S. Cisplatin plus etoposide as second-line treatment in advanced ovarian carcinoma, Cancer Treat. Rep. 70, 893-895 (1986).
25. 25. Hoskins, P. J., and Swenerton, K. D. Oral etoposide is active against platinum-resistant epithelial ovarian cancer, J. Clin. Oncol. 12, 60-63 (1994).
26. 26. de Wit, R., van der Burg, M. E. L., Gaast, A., Logmans, A., Stoter, G., and Verweij, J. Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy, Ann. Oncol. 5, 656-657 (1994).
27. 27. Seymour, M. T., Mansi, J. L., Gallagher, C. J., Gore, M. E., Harper, P. G., Evans, T. R. J., Edmonds, P. M., and Slevin, M. L. Protracted oral etoposide in epithelial ovarian cancer: A phase II study in patients with relapsed or platinum-resistant disease, Br. J. Cancer 69, 191-195 (1994).
28. 28. Eckhardt, S., Hernadi, Z., Thurzo, L., Telekes, A., Sopkova, B., Mechl, Z., Pawlicki, M., and Kerpel-Fronius, S. Phase II clinical evaluation of etoposide (VP-16-213, Vepesid) as a second-line treatment in ovarian cancer, Oncology 47, 289-295 (1990).
29. 29. Dittrich, C., Baur, M., Vavra, N., Hudec, M., Fazeny, B., Barrada, M., Salzer, H., and Sevelda, P. Etoposide and carboplatin as salvage and first-line therapy in ovarian cancer patients, Ann. Oncol. 4, 697-699 (1993).
30. 30. Baker, T. R., Piver, M. S., and Hempling, R. E. The addition of etoposide and ifosfamide to cisplatin as second line therapy in ovarian carcinoma, Eur. J. Gynaecol. Oncol. 14, 18-22 (1993).
31. 31. Fanning, J., Hilgers, R. D., and Hutson, E. Carboplatin, etoposide and ifosfamide as second-line treatment for ovarian cancer, Am. J. Clin. Oncol. 17, 335-337 (1994).
32. 32. Thigpen, T., Blessing, J., Ball, H., Hummel, S., and Barrett, R. Phase II trial of taxol as second-line therapy for ovarian carcinoma: A Gynecologic Oncology Group Study, Proc. Am. Soc. Clin. Oncol. 10, 604 (1990).
33. 33. McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, D. K., and Donehower, R. C. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms, Ann. Intern. Med. 111, 273-279 (1989).
34. 34. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., and Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N. Engl. J. Med. 334, 1-6 (1996).
35. 35. Johnston, C. M., Pearl, M. L., Reynolds, R. K., Roberts, J. A., and Morley, G. W. Treatment of refractory ovarian carcinoma with paclitaxel and cisplatin after treatment failure with single-agent paclitaxel, Eur. J. Gynaecol. Oncol. 16, 439-447 (1995).
36. 2): Unexpected high incidence of peripheral neuropathy, presented at the 27th Annual Meeting of the Society of Gynecologic Oncologists, February 11, 1996.